IGHE and asthma: Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe and severe persistent allergic (IgE-mediated) asthma in reducing the risk of exacerbations, hospitalization, and emergency room (ER) visits [4, 8].